Immuron (IMRN) Struggles After Announcing Trial Results
Immuron Limited (NASDAQ:IMRN) is a biotechnology company that provides a medicine to prevent diarrhea and is also developing similar medicines.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 45,782 | $34,909 | +135% | 0% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 57,381 | $43,753 | 0% | |
| 2. | 22,458 | $17,124 | 0% | |
| 3. | 14,116 | $10,763 | 0% | |
| 4. | 4,700 | $3,584 | 0% | |
| 5. | 4,496 | $3,425 | 0% |